Vestmark Advisory Solutions Inc. Reduces Holdings in Zoetis Inc. $ZTS

Vestmark Advisory Solutions Inc. lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 19.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,441 shares of the company’s stock after selling 3,645 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Zoetis were worth $2,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $27,000. Saudi Central Bank purchased a new stake in Zoetis in the 1st quarter valued at about $29,000. REAP Financial Group LLC raised its holdings in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC lifted its position in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ZTS shares. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Stifel Nicolaus set a $140.00 target price on Zoetis in a research report on Tuesday, November 4th. Finally, UBS Group lowered their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Price Performance

Zoetis stock opened at $120.20 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $117.26 and a 52-week high of $181.85. The firm has a market cap of $52.97 billion, a PE ratio of 20.69, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company’s 50 day moving average is $144.21 and its two-hundred day moving average is $152.63.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.